Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.Circulation · 2021 · on this map
   Trial
2. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.Circulation · 2020 · on this map
   Trial
3. Novel risk model for predicting incident atrial fibrillation in patients taking ω-3 fatty acid: sub-analysis of the STRENGTH randomized trial.American journal of preventive cardiology · 2026
   Article
4. Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement.Clinical kidney journal · 2026
   Review
5. Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of lipid and atherosclerosis · 2025
   Review
6. Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients.Pharmaceuticals (Basel, Switzerland) · 2024
   Review
7. ISCHEMIA trial - a hundred million dollar 'Trial' under trial!Indian journal of thoracic and cardiovascular surgery · 2022
   Article
8. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition.Seminars in immunology · 2022
   Review
9. EPA and DHA containing phospholipids have contrasting effects on membrane structure.Journal of lipid research · 2021
   Article
10. Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.Arteriosclerosis, thrombosis, and vascular biology · 2020
    Review
11. Fibrate pharmacogenomics: expanding past the genome.Pharmacogenomics · 2020
    Article
12. A New E-Series Resolvin: RvE4 Stereochemistry and Function in Efferocytosis of Inflammation-Resolution.Frontiers in immunology · 2020
    Article

Corrections and comments

• Commented on by
  Novel antibody-based reversal agent for ticagrelor.2019
• Comment on
  Cardiovascular Risk Reduction with Icosapent Ethyl.2019
• Comment on
  Cardiovascular Risk Reduction with Icosapent Ethyl.2019

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as